伊托必利对肝衰竭大鼠胃肠道动力的影响

发布时间：2018-12-19 07:16

【摘要】：目的观察伊托必利对肝衰竭大鼠胃肠道动力的影响,探讨其可能的作用机制。方法 60只Wistar大鼠随机分为肝衰竭模型组(以下简称模型组)、肝衰竭模型+伊托必利治疗组(以下简称治疗组)和对照组,采用葡聚糖蓝-2000为胃肠内标记物,测定大鼠胃肠道传输的改变,通过放射免疫和免疫组织化学法观察大鼠胃窦、小肠组织中胃动素(MTL)的含量和分布变化。结果与对照组比较,模型组大鼠胃肠道动力明显减弱(P0.01),胃窦、十二指肠组织中MTL的含量及分布无明显减少(P0.05);但伊托必利治疗后,大鼠胃肠道传输明显改善(P0.05),胃、十二指肠组织中MTL的含量和分布明显升高,与模型组比较差异有统计学意义(P0.05)。结论伊托必利能明显改善肝衰竭大鼠的胃肠道功能,其机制可能与MTL有关。
[Abstract]:Objective to observe the effect of itopride on gastrointestinal motility in rats with liver failure and to explore its possible mechanism. Methods Sixty Wistar rats were randomly divided into three groups: hepatic failure model group (model group), hepatic failure model group treated with itopride and control group. Dextran blue 2000 was used as gastrointestinal marker. The contents and distribution of motilin (MTL) in rat antrum and small intestine were observed by radioimmunoassay and immunohistochemistry. Results compared with the control group, the gastrointestinal motility of the model group was significantly decreased (P0.01), and the content and distribution of MTL in the antrum and duodenum of the model group were not significantly decreased (P0.05). However, after treatment with itopride, the gastrointestinal tract transport was significantly improved (P0.05), the content and distribution of MTL in gastric and duodenal tissues were significantly increased, compared with the model group, the difference was statistically significant (P0.05). Conclusion itopride can obviously improve gastrointestinal function in rats with liver failure, and its mechanism may be related to MTL.
【作者单位】：福建医科大学孟超肝胆医院肝病消化内科;
【基金】：福州市科技局科技计划项目(No:2011-S-69-3)
【分类号】：R575.3

【相似文献】